Shares of state-run Bank of Baroda (BoB) experienced a significant decline, falling nearly 8% over two trading days. This downturn followed the bank's announcement of an out-of-court settlement amounting to $600 million (approximately Rs 5,700 crore) with the joint administrators of NMC Health PLC, NMC Healthcare Ltd, and NMC Holding Ltd.
On Friday, the stock slid 3.83% to hit a low of Rs 250.20 in early trade, contributing to a total slump of 7.85% across two trading sessions. The settlement, which was paid by BoB's Abu Dhabi Branch, resolves complex legal proceedings.
The case involved intricate proceedings under ADGM (Abu Dhabi Global Market) and UK insolvency law, alongside UAE civil law, concerning NMC Health, NMC Holding, and NMC Healthcare. The trial in the ADGM proceedings had commenced on March 23, 2026, with English proceedings previously stayed pending its outcome.
Bank of Baroda stated that all claims and causes of action between the parties have been resolved without any admission of liability or wrongdoing. The settlement agreement and its specific terms remain confidential, with the bank's liability in these proceedings capped at the $600 million sum.
Following the agreement, the ADGM proceedings have been discontinued, and the English proceedings are in the process of being discontinued.
In a separate development, Bank of Baroda also reported robust growth in its global business. As of June 30, 2026, its global business expanded by 15.46% year-on-year (YoY) to Rs 30.51 lakh crore. Global advances saw an increase of 17.42% YoY to Rs 14.17 lakh crore, while global deposits grew by 13.81% YoY, reaching Rs 16.34 lakh crore during the same period.
From a technical perspective, BoB's stock was trading below its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs). Its 14-day relative strength index (RSI) stood at 34.64, indicating it was not yet in oversold territory (typically below 30).
According to Trendlyne data, the bank's standalone price-to-earnings (P/E) ratio was 6.58, with a price-to-book (P/B) value of 1.04. Earnings per share (EPS) were reported at 38.72, and return on equity (RoE) at 15.82. The stock's one-year beta of 1.35 suggests relatively high volatility.